Biopharma · FDA Approvals · Stock

AZR Azora Therapeutics

Azora Therapeutics Inc is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. Azora owns the royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a pr…

Assets on file: AT177

Catalyst calendar

Dated catalysts for AZR, including recently decided ones.

Recent first-hand events

Every first-hand event for AZR, newest first.

Instant stream — events appear as soon as they are filed.
Decision-gradeMaterialNotableMinor
Nov 12, 2026
09:06 PM
AZRAzora Therapeutics, Inc.

Azora Therapeutics Reiterates AT177 IND Submission and Phase 1a Initiation on Track for H1 2027

This quarterly earnings release and business update restates that IND-enabling studies for AT177 (colon-targeted AhR agonist) are continuing and that submission of the IND plus initiation of the Phase 1a SAD/MAD trial remain on track for the first half of 2027. The document also notes completed GLP toxicology studies and pre-IND FDA feedback.

OtherSEC 8-K

Peers by market cap

Companies in the same sector closest to AZR in market value.

AZR FDA Calendar & Catalysts — Azora Therapeutics | Biopharma · FDA Approvals | SimianX AI